3 years on, FDA still evaluating Qdenga dengue vaccine application

MANILA, Philippines — The proposed new generation anti-dengue vaccine remains under review by the Food and Drug Administration (FDA) three years after it applied for registration, according to Malacañang. Citing a statement from the Department of Health (DOH), Palace press officer Claire Castro said the application of Japanese pharmaceutical company Takeda for the certificate of product registration of its Qdenga vaccine is still under study by the FDA to assess its safety and effectiveness for use in the country. This was amid renewed concerns over the mosquito-borne disease as the rainy season begins and the number of dengue cases in the […]... Keep on reading: 3 years on, FDA still evaluating Qdenga dengue vaccine application